Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Active, not recruiting · NCT03240211 · Registry updated 2026-04-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-04-07 | NCT03240211 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 26 |
| University of Virginia | 201 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allegheny Health Network | Pittsburgh | United States | 1 |
| University of Virginia | Charlottesville | United States | 5 |